Adipose Tissue & Uremia

NCT02902705 | Completed

• 1 other identifier: 2008.520
• Study Type: interventional
• Target: 23
• Locations: 1 country
• Sites: 1

Brief Summary

Many metabolic disturbances, such as protein-energy wasting, inulin resistance, and dyslipidemia are common features of chronic kidney disease (CKD). However, to date, the underlying mechanisms of these disturbances remain elusive. Many in vitro studies have demonstrated that white adipose cells exhibit dysfunctions in conditions that mimics uremic environment. In good agreement, several animal experiments have reported that chronic kidney disease was associated with lipoatrophy, adipose tissue dysfunction and ectopic lipid redistribution. The goal of this protocol is to collect and study structural and metabolic properties of white adipose tissue in CKD stage V patients to evidence adipose tissue dysfunction associated with CKD. The primary outcome measure will be the cellularity of the adipose tissue (i.e. size of the adipose cells) and the secondary measure to study the gene expression profile using microarray and metabolic properties of adipose tissue (i.e. lipogenesis). To this end, 15 male adult volunteers and 15 non-diabetic and non-dialyzed CKD stage V patients, matched for age, gender and body mass index (BMI) will be recruited at the Departments of Nephrology or Urology of Lyon University Hospital (Lyon, France). The biopsies of abdominal subcutaneous white adipose tissue (2-3 g) will be performed during elective urologic surgery (i.e. peritoneal dialysis catheter for CKD patients and radical prostatectomy for non CKD patients).

Conditions

Chronic Kidney Disease - Stage V

Keywords

White adipose tissue; chronic kidney disease; uremia; adipocytes

Outcome Measures

Primary Outcomes (1)

• Mean adipocyte size (in µm) in subcutaneous white adipose tissue removed during biopsy, measured with a Beckman Coulter

  The biopsies of abdominal subcutaneous white adipose tissue (2-3 g) will be performed during elective surgery (i.e. peritoneal dialysis catheter for CKD patients and radical prostatectomy for non CKD patients). 50-100 mg will be fixed in osmium tetroxide for cellularity measurement i.e. measurement of adipose cell size. Adipose cell size will be determined by a Beckman Coulter Multisizer IV (Beckman Coulter) with a 400 µm aperture. The range of cell sizes that can effectively be measured using this aperture is 20-240 µm. The instrument will be set to count 1,000 particles, and the fixed-cell suspension will be diluted so that coincident counting remains \<10%. Cell-size distributions will be drawn from measurement of at least 12,000 cell diameters for each patient. The mean fat cell volume will then be compared using Student t test or Mann \& Whitney U tests.

  Day 1, the day of surgery (one day after inclusion)

Study Arms (2)

Chronic Kidney disease patients - stage V

EXPERIMENTAL

Male adults non-diabetic and non-dialyzed CKD stage 5 patients. All the CKD patient will be recruited at the Department of Nephrology of Edouard Herriot University Hospital (Lyon, France).

Other: Biopsy of abdominal subcutaneous white adipose tissue (2-3 g)

Non Chronic Kidney Disease patients

OTHER

Non CKD male adults matched for age, gender and body mass index (BMI) with CKD patients. All the non - CKD patient will recruited from Department of recruited at the Department of Urology of Edouard Herriot University Hospital (Lyon, France).

Other: Biopsy of abdominal subcutaneous white adipose tissue (2-3 g)

Interventions

Biopsy of abdominal subcutaneous white adipose tissue (2-3 g) OTHER

The biopsies of abdominal subcutaneous white adipose tissue (2-3 g) will be performed during elective surgery (i.e. peritoneal dialysis catheter) for CDK patients or during elective urologic surgery (e.g. radical prostatectomy) for Non-CDK patients. 50-100 mg will fixed in osmium tetroxide for cellularity measurement and 1g of fresh adipose tissue were used from adipocyte isolation. The remnant part of the biopsies will be snap frozen in liquid nitrogen and stored at -80°C until use (gene expression).

Chronic Kidney disease patients - stage V; Non Chronic Kidney Disease patients

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• CKD (Chronic Kidney Disease) and non-CKD patients:
• At least 18 years of age
• Able and willing to provide informed consent
• Male gender
• Normal fasting glucose (less than 6 mmol/l )
• No evidence of significant concurrent illness
• BMI \<30 kg/m2
• Non acidotic (bicarbonate \>20 mmol/L)
• Normal coagulation profile
• CKD patients:
• eGFR (estimated Glomerular Filtration Rate)\< 25 mL/min/m2 before the beginning of renal suppletion therapy
• Non-CKD patients:
• eGFR \>50 mL/min/m2

You may not qualify if:

• A known diagnosis of diabetes mellitus
• enrolled in a other study that may confound results of this study.
• Have been treated with: corticosteroids or insulin or oral diabetic medications within 8 days prior to study entry
• Unwilling and/or not able to give written consent
• Patient with active systemic bacterial, viral or fungal infections

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Service de Néphrologie, dialyse, hypertension artérielle - Pavillon P - Hôpital Edouard Herriot -

Lyon, 69003, France

Location

Related Publications (1)

• Luce M, Barba C, Yi D, Mey A, Roussel D, Bres E, Benoit B, Pastural M, Granjon S, Szelag JC, Laville M, Arkouche W, Bouchara A, Nyam E, Fouque D, Soulage CO, Koppe L. Accumulation of natriuretic peptides is associated with protein energy wasting and activation of browning in white adipose tissue in chronic kidney disease. Kidney Int. 2020 Sep;98(3):663-672. doi: 10.1016/j.kint.2020.03.027. Epub 2020 Apr 23.

  PMID: 32739210 BACKGROUND

MeSH Terms

Conditions

Renal Insufficiency, Chronic; Uremia

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 12, 2016
• First Posted: September 16, 2016
• Study Start: September 1, 2009
• Primary Completion: July 1, 2015
• Study Completion: July 1, 2015
• Last Updated: September 9, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)